- Home
- GF vs LRMR Comparison
GF vs LRMR Comparison
Compare GF & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GF
- LRMR
- Stock Information
- Founded
- GF 1990
- LRMR N/A
- Country
- GF Germany
- LRMR United States
- Employees
- GF N/A
- LRMR N/A
- Industry
- GF Investment Managers
- LRMR Biotechnology: Pharmaceutical Preparations
- Sector
- GF Finance
- LRMR Health Care
- Exchange
- GF Nasdaq
- LRMR Nasdaq
- Market Cap
- GF 155.4M
- LRMR 183.8M
- IPO Year
- GF N/A
- LRMR N/A
- Fundamental
- Price
- GF $10.40
- LRMR $2.33
- Analyst Decision
- GF
- LRMR Strong Buy
- Analyst Count
- GF 0
- LRMR 9
- Target Price
- GF N/A
- LRMR $19.00
- AVG Volume (30 Days)
- GF 28.1K
- LRMR 965.6K
- Earning Date
- GF 01-01-0001
- LRMR 05-08-2025
- Dividend Yield
- GF 0.82%
- LRMR N/A
- EPS Growth
- GF N/A
- LRMR N/A
- EPS
- GF N/A
- LRMR N/A
- Revenue
- GF N/A
- LRMR N/A
- Revenue This Year
- GF N/A
- LRMR N/A
- Revenue Next Year
- GF N/A
- LRMR N/A
- P/E Ratio
- GF N/A
- LRMR N/A
- Revenue Growth
- GF N/A
- LRMR N/A
- 52 Week Low
- GF $7.38
- LRMR $1.61
- 52 Week High
- GF $9.41
- LRMR $11.20
- Technical
- Relative Strength Index (RSI)
- GF 63.96
- LRMR 53.85
- Support Level
- GF $10.11
- LRMR $1.76
- Resistance Level
- GF $10.32
- LRMR $2.51
- Average True Range (ATR)
- GF 0.26
- LRMR 0.20
- MACD
- GF 0.07
- LRMR 0.10
- Stochastic Oscillator
- GF 100.00
- LRMR 80.00
About GF New Germany Fund Inc. (The)
NEW GERMANY FUND INC is a non-diversified, closed-end management investment company. As the investment objective, the fund seeks long-term capital appreciation through investment in middle-market German equities. The fund's portfolio of investment includes investments in different sectors such as the industrials, information technology, material, consumer discretionary, Communication Services, Financials, Consumer Staples, Real Estate, Utilities, Healthcare, Energy, and others. Its portfolio is geographically diversified across the Netherlands, Germany, and Luxembourg.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.